Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-01-09 Investor Presentation
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 9, 2024, by Sana Biotechnology, Inc. It primarily announces the furnishing of a corporate presentation to be discussed at the 42nd Annual J.P. Morgan Healthcare Conference. The text states that the corporate presentation is attached as Exhibit 99.1 and is incorporated by reference. The document does not contain financial statements or detailed financial data but rather serves as a disclosure of the presentation material. The length of the document is 4412 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the corporate presentation) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2024-01-09 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-08 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-08 English
PRIMARY DOCUMENT
Director's Dealing
2023-12-18 English
Regulatory Filings 2023
Regulatory Filings
2023-12-15 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 11, 2023, by Sana Biotechnology, Inc. The key content is the release of an updated corporate presentation, which is furnished as an exhibit to the filing. The text explicitly states that the information is furnished under Item 7.01 Regulation FD Disclosure and includes a corporate presentation as Exhibit 99.1. There are no financial statements or detailed financial data included in the text itself, only a reference to the presentation. The document length is 5262 characters, which is relatively short and consistent with an announcement or furnishing of a presentation rather than a full report. According to the classification rules, a document that primarily furnishes a presentation to investors without substantive financial data should be classified as an Investor Presentation (IP).
2023-12-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.